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A B S T R A C T
Background
Strength training or aerobic exercise programmes might optimise muscle and cardiorespiratory function and prevent additional disuse
atrophy and deconditioning in people with a muscle disease. This is an update of a review first published in 2004.
Objectives
To examine the safety and efficacy of strength training and aerobic exercise training in people with a muscle disease.
Search methods
We searched the Cochrane Neuromuscular Disease Group Specialized Register (July 2012), CENTRAL (2012 Issue 3 of 4), MEDLINE
(January 1946 to July 2012), EMBASE (January 1974 to July 2012), EMBASE Classic (1947 to 1973) and CINAHL (January 1982
to July 2012).
Selection criteria
Randomised or quasi-randomised controlled trials comparing strength training or aerobic exercise programmes, or both, to no training,
and lasting at least six weeks, in people with a well-described diagnosis of a muscle disease.
We did not use the reporting of specific outcomes as a study selection criterion.
Data collection and analysis
Two authors independently assessed trial quality and extracted the data obtained from the full text-articles and from the original
investigators. We collected adverse event data from included studies.
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Main results
We included five trials (170 participants). The first trial compared the effect of strength training versus no training in 36 people
with myotonic dystrophy. The second trial compared aerobic exercise training versus no training in 14 people with polymyositis and
dermatomyositis. The third trial compared strength training versus no training in a factorial trial that also compared albuterol with
placebo, in 65 people with facioscapulohumeral muscular dystrophy (FSHD). The fourth trial compared combined strength training
and aerobic exercise versus no training in 18 people with mitochondrial myopathy. The fifth trial compared combined strength training
and aerobic exercise versus no training in 35 people with myotonic dystrophy type 1.
In both myotonic dystrophy trials and the dermatomyositis and polymyositis trial there were no significant differences between training
and non-training groups for primary and secondary outcome measures. The risk of bias of the strength training trial in myotonic
dystrophy and the aerobic exercise trial in polymyositis and dermatomyositis was judged as uncertain, and for the combined strength
training and aerobic exercise trial, the risk of bias was judged as adequate. In the FSHD trial, for which the risk of bias was judged
as adequate, a +1.17 kg difference (95% confidence interval (CI) 0.18 to 2.16) in dynamic strength of elbow flexors in favour of the
training group reached statistical significance. In the mitochondrial myopathy trial, there were no significant differences in dynamic
strength measures between training and non-training groups. Exercise duration and distance cycled in a submaximal endurance test
increased significantly in the training group compared to the control group. The differences in mean time and mean distance cycled
till exhaustion between groups were 23.70 min (95% CI 2.63 to 44.77) and 9.70 km (95% CI 1.51 to 17.89), respectively. The risk
of bias was judged as uncertain. In all trials, no adverse events were reported.
Authors’ conclusions
Moderate-intensity strength training inmyotonic dystrophy and FSHDand aerobic exercise training in dermatomyositis and polymyosi-
tis and myotonic dystrophy type I appear to do no harm, but there is insufficient evidence to conclude that they offer benefit. In mito-
chondrial myopathy, aerobic exercise combined with strength training appears to be safe and may be effective in increasing submaximal
endurance capacity. Limitations in the design of studies in other muscle diseases prevent more general conclusions in these disorders.
P L A I N L A N G U A G E S U M M A R Y
Strength training or comprehensive aerobic exercise training for muscle disease
Strength training, which is performed to improve muscle strength and muscle endurance, or aerobic exercise programmes, which are
designed to improve cardiorespiratory endurance, might optimise physical fitness and prevent additional muscle wasting in people with
muscle disease. However, people with muscle disease and some clinicians are still afraid of overuse and have a cautious approach to
training. This updated review (most recent date of search 2 July 2012) included two eligible trials of strength training in people with
facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy (101 participants), two trials of strength training combined
with aerobic exercise in people with mitochondrial myopathy (18 participants) and myotonic dystrophy type I (35 participants) and one
trial of aerobic exercise in people with polymyositis and dermatomyositis (14 participants). These trials showed that moderate-intensity
strength training in people with myotonic dystrophy or with FSHD, and aerobic exercise training in people with dermatomyositis or
polymyositis appear not to harm muscles. Strength training combined with aerobic exercise appears to be safe in myotonic dystrophy
type I and may be effective in increasing endurance in people with mitochondrial myopathy. Evidence suggests that strength training
is not harmful in people in FSHD, myotonic dystrophy, mitochondrial disorders and dermatomyositis and polymyositis, but further
research is needed to determine potential benefit.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Strength training compared to usual care for facioscapulohumeral muscular dystrophy
Patient or population: facioscapulohumeral muscular dystrophy
Settings: at home
Intervention: strength training
Comparison: usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Usual care Strength training
Difference in dynamic
muscle strength of el-
bow flexors
quantitative muscle as-
sessment fixedmyometry
Follow-up: mean 52
weeks
The mean difference in
dynamic muscle strength
of elbow flexors in the
control groups was
1.39 Nm
The mean difference in
dynamic muscle strength
of elbow flexors in the in-
tervention groups was
1.17 higher
(0.18 to 2.16 higher)
65
(1 study)
⊕⊕⊕©
moderate1
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 The lower confidence limit crosses the minimal important difference.
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B A C K G R O U N D
The term ’muscle disease’ comprises a large group of conditions.
Skeletal muscles are primarily affected but in some disorders other
organ systems may also be involved. Most conditions are progres-
sive, causing the muscles to gradually weaken over time. When
a person is diagnosed as having a muscle disease, questions arise
about the prognosis, possible interventions and genetics.However,
people with muscle disease are usually also concerned about every-
day issues such as participation in sports, work and hobbies. We
cannot give evidence-based advice about these issues, because we
do not know how physical exercise affects the diseased muscular
system or the cardiorespiratory system. To answer these questions,
controlled trials of aerobic exercise and strength training in people
with a muscle disease are needed.
Weakness and impaired cardiorespiratory function are common
in people with muscle disease; pain and fatigue may also be com-
mon symptoms, all of which contribute to a decreased quality of
life. In healthy persons the best intervention to improve strength
and cardiorespiratory function is physical training. Strength train-
ing or aerobic exercise programmes in people with muscle disease
might maximise muscle and cardiorespiratory function and pre-
vent additional disuse atrophy (Vignos 1983). However, reports of
progression of weakness after exercise in people with myopathies
have encouraged a cautious approach to training (Brouwer 1992;
Fowler 1984; Johnson 1971). Therefore, many people with amus-
cle disease were advised to avoid physical exertion (Fowler 1982).
Thus the benefit from strength training or aerobic exercise train-
ing in muscle diseases is still not clear (Kilmer 1998).
The relative rarity of many muscle diseases has led researchers
to group participants with different neuromuscular disorders to-
gether in one study, including myopathies, neuropathies and mo-
tor neuron disease (Aitkens 1993; Dawes 2006; Kilmer 1994;
Kilmer 2005; McCartney 1988; Milner-Brown 1988a; Milner-
Brown 1988b;Wright 1996). As the pathophysiology of these dis-
orders differs, their reaction to an intervention might also be dif-
ferent. Therefore, conclusions about the effect of training derived
from these mixed populations cannot readily be extrapolated to
people with specific muscular disorders (Lindeman 1995).
In this review we systematically analysed randomised controlled
trials (RCTs) of these interventions for people with specified mus-
cle diseases. This review was first published in 2004, with themost
recent update of the searches in 2012.
O B J E C T I V E S
To examine the safety and efficacy of strength training and aerobic
exercise training in people with a muscle disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all RCTs or quasi-RCTs that made any of the follow-
ing comparisons:
• strength training versus no training;
• aerobic exercise training versus no training;
• combined strength training and aerobic exercise versus no
training.
Quasi-RCTs are trials that allocate participants to experimental or
control groups based on a method that is not truly random, for
example, hospital record number or date of birth.
Types of participants
We selected all trials that included participants with a well-de-
scribed diagnosis of a muscle disease, such as inflammatory my-
opathies,metabolicmyopathies,muscular dystrophies,muscle dis-
eases with myotonia and other well-defined myopathies. We de-
cided not to include studies looking at strength training or aerobic
exercise training for people in whom muscle weakness was not
the primary feature, but might have been secondary to chronic
renal insufficiency, chronic heart failure, renal or heart transplan-
tation, or corticosteroid use. We did not review the effects of res-
piratory muscle training. We did not include studies regarding
aerobic exercise training for McArdle disease because there is a
separate Cochrane review available for this metabolic myopathy
(Quinlivan 2011). We excluded studies in which participants had
a variety of muscle diseases if we could not obtain results for each
condition separately. We assessed the diagnostic criteria of each
study; diagnosis has to be confirmed by muscle biopsy or genetic
testing.
Types of interventions
To date, there is no evidence or recommendation for a minimum
duration of training in muscle disease. However, in the first six
weeks, the change in muscle strength or aerobic capacity is gener-
ally caused by neural adaptation. Therefore, we included all forms
of strength training and aerobic exercise training lasting at least
six weeks. We excluded all studies using a within-subjects design
with the non-exercised limb as a control. If exercises are performed
to increase muscle strength on one side of the body, voluntary
strength can increase on the contralateral side. This concept is
called cross-education, andhas beendescribedwith different forms
of exercises. A meta-analysis of 16 randomised studies concluded
that, on average, the magnitude of cross-education is eight per
cent of the initial strength of the untrained limb (Munn 2004).
Neural adaptations to training and learning effects due to testing
are postulated as explanations (Lee 2007; Munn 2005; Sale 1988;
Shima 2002). Moreover, the results may well be confounded by
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the presence of asymmetric weakness of both limbs, as the absolute
gain in muscle strength resulting from strength training is related
to pre-exercise muscle weakness (Kilmer 2002). For this reason, a
non-exercised limb is not an appropriate control, even if training
is randomly assigned. For this reason, we have excluded studies
using such a within-subjects design.
Definitions
• Training, or physical fitness training: a planned, structured
regimen of regular physical exercise deliberately performed to
improve one or more of the following components of physical
fitness: cardiorespiratory fitness, body composition, muscle
strength and endurance, and flexibility (Garber 2011).
• Strength training: a systematic program of exercises
designed to increase an individual’s ability to exert or resist force
using, for example, weights, weight machines or elastic cords
(Garber 2011).
• Aerobic exercise training, or cardiorespiratory fitness
training: training that is designed to improve the capacity and
efficiency of aerobic energy-producing systems and is effective
for improving cardiorespiratory endurance. It consists of an
activity or combination of activities that uses large muscle
groups, that can be maintained continuously, and is rhythmical
and aerobic in nature, for example walking, running, cycling,
aerobic dance exercise or swimming (Garber 2011).
Types of outcome measures
Primary outcomes
The primary outcome measure for strength training was:
• change in muscle strength, expressed in measures of static
(that is, isometric) or dynamic strength between baseline and six
weeks.
The primary outcome measure for aerobic exercise training was:
• change in aerobic capacity, expressed in measures of work
capacity between baseline and six weeks.
Secondary outcomes
The secondary outcome measure specific to strength training was:
• change in muscle endurance muscle endurance or muscle
fatigue between baseline and six weeks.
The secondary outcome measure specific to aerobic exercise train-
ing was:
• change in aerobic capacity, expressed in measures of oxygen
consumption, parameters of cardiac function or parameters of
respiratory function between baseline and six weeks.
Secondary outcome measures applicable to both strength training
and aerobic exercise training showing a change from baseline and
six weeks were:
• timed-scored functional assessments of muscle
performance, such as a six-minute walk test (Florence 2008);
• quality of life measures, such as the Short Form 36 (SF-36)
Health Survey (Ware 2000);
• parameters of muscle membrane permeability (serum
creatine kinase level, myoglobin level) to assess safety;
• pain assessed by an analogue pain scale (Kahl 2005);
• experienced fatigue assessed by questionnaires, eg. Checklist
Individual Strength (CIS-fatigue) (Vercoulen 1999);
• adverse effects requiring withdrawal of the participant from
the study: acute rhabdomyolysis, increasing muscle pain, injury,
etc;
We compared data on outcome measures at baseline with those
obtained after at least six weeks of training. When there were as-
sessments at more than one time (during the intervention, after
cessation of the intervention), our preference was for data on out-
come measures obtained at the end of the intervention.
Search methods for identification of studies
We searched the following databases: the Cochrane Neuro-
muscular Disease Group Specialized Register (July 2012), the
Cochrane Central Register of Controlled Trials (CENTRAL, in
The Cochrane Library 2012, Issue 7 of 12), MEDLINE (January
1946 to July 2012), EMBASE (January 1974 to July 2012), EM-
BASEClassic (1947 to 1973) and CINAHL (January 1982 to July
2012). We reviewed the bibliographies of the trials identified and
other reviews of the subject, and contacted some of the authors in
the field to identify additional published and unpublished data.
Data collection and analysis
Selection of studies
Two review authors (Voet, van der Kooi) checked the references
identified by the search strategy. We obtained the full text of all
potentially relevant studies for independent assessment by both
authors. We decided which trials fitted the inclusion criteria.
Data extraction and management
Two review authors (Voet, van der Kooi) independently extracted
the data from the included trials onto a specially designed data
extraction form, and graded the risk of bias and certain other
aspects of the design of the included trials.
Assessment of risk of bias in included studies
We assessed the risk of bias and other aspects according to the
Cochrane approach using the updated guidance in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
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We assessed the included studies for randomisation sequence gen-
eration, allocation concealment, blinding (participants and out-
come assessors), incomplete outcome data, selective outcome re-
porting and other sources of bias. When there was uncertainty,
we contacted authors for clarification. We resolved disagreements
about fulfilment of inclusion or quality criteria by discussion be-
tween the two authors. We made a judgement on each of the
’Risk of bias’ criteria, of “High risk of bias”, “Low risk of bias” or
“Unclear risk of bias”. Whenever characteristics of study design or
drop-out rates were likely to cause a higher risk of bias, we planned
to make a note of this and investigate the possibility of differences
in treatment effects varying with the degree of this problem.
Data synthesis
We intended to combine trial results for appropriate pairings of
treatments by calculating a mean of the difference between their
effects using the Cochrane statistical package Review Manager 5
(RevMan) (RevMan 2012). Because pooling of the results of tri-
als in different muscle diseases is usually not appropriate, we ex-
pressed, when possible, the results per muscle disease as mean dif-
ferences (MD) with 95% confidence intervals (CI) for continu-
ous outcomes, and risk ratios (RR) with 95% CI for dichotomous
outcome measures. The intended testing for heterogeneity, and
consequent actions, turned out to be unnecessary.
Subgroup analysis and investigation of heterogeneity
We decided, in advance, not to perform subgroup analyses based
on sex or age because we anticipated that the differences in mus-
cle disease severity would have a much bigger influence on out-
come than sex or age. Moreover, the American College of Sports
Medicine stated in their Position Stand (Garber 2011) that rel-
ative improvements resulting from aerobic and strength training
are similar for young and old, male and female.We presented data
for individual muscle diseases separately. As the pathophysiology
of each muscle disease differs, we considered that their reaction
to training might be different. If in future data are available for
meta-analysis, we will consider investigating the effect of different
durations of exercise or training intervention.
R E S U L T S
Description of studies
In this review, the search retrieved approximately 7400 records.
After assessing the titles and abstracts, we identified 61 studies for
potential inclusion: 26 completed trials that studied strength train-
ing as an intervention, 20 trials studying aerobic exercise training,
and 15 trials studying combined strength training and aerobic ex-
ercise, sometimes incorporated in more comprehensive rehabili-
tation programmes. Most strength training trials included people
with the following muscle diseases: slowly progressive dystrophies
(mostly myotonic dystrophy, limb-girdle dystrophies, facioscapu-
lohumeral muscular dystrophy (FSHD)) and in the older stud-
ies, non-specified progressive muscular dystrophies and inflamma-
tory myopathies. Studies on the effects of aerobic exercise train-
ing included mainly people with slowly progressive dystrophies
andmetabolic myopathies (mostly unspecified mitochondrial my-
opathies).
Studies have generally been limited by small sample sizes. We
excluded 48 studies because there was no randomised controlled
comparison between training and non-training participants and
six studies because of a within-subjects design (see Characteristics
of excluded studies).
Only seven studies were RCTs making a comparison between
training and non-training participants (Cejudo 2005; Dawes
2006; Kierkegaard 2011; Lindeman 1995; van der Kooi 2004;
Wiesinger 1998a;Wiesinger 1998b). Regrettably, the extension of
the initially randomised, controlled six-week aerobic exercise study
in people with dermatomyositis and polymyositis by Wiesinger et
al (Wiesinger 1998b) lost its randomised controlled design due
to a decision of the ethics committee. The randomised controlled
strength training combined with aerobic exercise trial which com-
pared eight weeks of walking and strengthening exercises versus no
training in 20 participants with different muscle diseases (Dawes
2006) has been excluded as both study groups consisted of partici-
pants with various muscle diseases and the outcomemeasures were
not presented for each muscle disease separately. As the patho-
physiology of each muscle disease differs, their reaction to training
might be different. It is not known if the effect of strength training
and aerobic exercise training is the same for every muscle disease.
Therefore, data should be presented and analysed for each disease
individually, and the power should be sufficient for each individual
disorder. For this reason, no conclusions can be drawn with regard
to the effect of exercise training for each specific muscle disease in
the trial. Finally, no specific details about the exercise programme
were provided and the risk of bias of the trial was high.
In conclusion, we included two strength training trials (Lindeman
1995; van der Kooi 2004), one aerobic exercise trial (Wiesinger
1998a) and two strength training combined with aerobic exer-
cise trials (Cejudo 2005; Kierkegaard 2011) (see Characteristics
of included studies). The first strength training trial compared the
effect of 24 weeks of training versus no training in 36 adults with
myotonic dystrophy and 30 adults with hereditary motor and sen-
sory neuropathy types I or II (Lindeman 1995). As this review is
concerned with muscle disease, we will not discuss the results of
the hereditary motor and sensory neuropathy participant group.
The aerobic exercise trial compared six weeks of cycle and step aer-
obics exercise with no training in nine adults with dermatomyosi-
tis and five adults with polymyositis (Wiesinger 1998a). The sec-
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ond strength training trial compared 52 weeks of strength training
versus no training in a factorial trial that also compared albuterol
with placebo after the first 26 weeks of training in 65 adult partic-
ipants with FSHD (van der Kooi 2004). Only the results for the
comparison strength training versus no training will be discussed
in this review. The first combined aerobic exercise and strength
training trial compared 12 weeks of cycle exercises and dynamic
and isokinetic strength training versus no training in 18 people
with mitochondrial myopathy (Cejudo 2005) (see Characteristics
of included studies). The second combined aerobic exercise and
strength training trial compared 14 weeks of balance exercises, aer-
obic activities, flexibility exercises, strength exercises and a brisk
walk versus no training in 35 people with myotonic dystrophy
type 1 (Kierkegaard 2011).
Risk of bias in included studies
Strength training trial in myotonic dystrophy
In the first myotonic dystrophy trial (Lindeman 1995), partic-
ipants with myotonic dystrophy were individually matched for
muscle strength and performance in a stair-climbing test. Within
each matched pair, participants were randomly assigned to the
training or control group. There was no published information on
the method of randomisation or on allocation concealment but
the first author (Lindeman) informed us that two independent
persons drew one sealed name per matched pair and allocated it to
the training or non-training group by tossing a coin. We graded
the intention to blind the clinical evaluators as adequate, although
approximately 20% of the myotonic dystrophy participants re-
vealed information to the clinical evaluators that resulted in un-
blinding during the course of the trial. The authors considered the
baseline comparability of the groups as suboptimal because the
training group had longer time scores for stair climbing (ameasure
of functional ability) and had higher knee torques (a measure of
muscle strength). They argued that the first three items could have
resulted in an underestimation of the training effect, whereas the
last item could have resulted in an overestimation of the training
effect. They concluded that the differences in experimental group
composition did not seem to explain the absence of differences in
outcomes between treatment groups. We considered the way the
authors presented and discussed the baseline differences as ade-
quate. Three of the initially 36 randomised participants withdrew
before disclosure of treatment allocation.The 33participants start-
ing the trial made 15 matched pairs. During the trial one person
dropped out because of knee problems. Because of the matched
pair design only complete pairs were analysed, thus eventually 28
of the initial 36 randomised participants were analysed. Follow-
up was therefore incomplete and analysis was not by intention-
to-treat. However, the flow path of participants was well docu-
mented.
Dermatomyositis and polymyositis trial
In the dermatomyositis and polymyositis trial (Wiesinger 1998a),
nine people with dermatomyositis and five with polymyositis were
randomly assigned to the training or control group using distinct
randomisation lists. The training group received six weeks of bi-
cycle exercises and step aerobics. Participants in the control group
did not undergo any training and continued their previous way
of life. There was no published information on allocation con-
cealment and our attempts to obtain further information on this
were not successful. During the strength measurements, the clini-
cal evaluator was blinded to the treatment allocation. The success
of blinding of assessors was not formally checked as blinding of
participants is not possible in an exercise study. There was no pub-
lished information on blinding during the other measurements.
Baseline characteristics were presented for both groups. The au-
thors considered the two groups to be well balanced with respect
to most baseline characteristics. There was complete follow-up of
all participants.
Facioscapulohumeral muscular dystrophy (FSHD)
In the FSHD trial (van der Kooi 2004), 65 participants were strati-
fied into two groups based onmuscle strength. Participants in both
strata were randomly assigned to one of the four treatment groups
according to a computer-generated randomisation list. The treat-
ments consisted of training plus albuterol, training plus placebo,
non-training plus albuterol, or non-training plus placebo. Train-
ing or non-training was the first intervention, starting just after
the baseline visit until after the final visit at 52 weeks. Information
on the assignment to training or non-training was disclosed to
the participants by the physical therapist (supervising the training
programme) after their baseline visit. The clinical evaluator was
blinded for the assignment to both interventions. The participants,
physical therapist and the neurologist evaluating side effects were
blinded to the treatment allocation. The blinding of the clinical
evaluator was considered adequate, although one of the main sec-
ondary outcome measures, the one-repetition maximum (1RM)
measurement for assessing dynamic strength, was performed by
the physical therapist who supervised the training, and who was
therefore not blinded to the allocation to training or non-training.
Allocation to the training or non-training group was unmasked in
three cases, due to unintentional remarks. The success of blinding
was not formally checked. Baseline characteristics were presented
for all treatment groups. One participant stopped training but still
attended all trial visits, resulting in complete follow-up of all par-
ticipants. Data analysis was by the intention-to-treat principle. As
no statistically significant interactions between the two interven-
tions (that is, training versus non-training) could be detected, the
effect sizes, being the differences in mean change from baseline,
were presented for each intervention.
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Combined aerobic exercise and strength training trial in
mitochondrial myopathy
In the mitochondrial myopathy trial (Cejudo 2005), 20 partic-
ipants were randomly assigned to the training or control group.
There was no published information on the method of randomi-
sation, allocation concealment, or blinding of the evaluators. The
author (Cejudo) informed us that participants were randomly as-
signed according to a computer generated randomisation list. The
evaluators were not blinded to the intervention allocation, but
knew to which group each participant was assigned. One partic-
ipant in each group failed to finish the study for personal rea-
sons. Baseline characteristics were presented for both groups, ex-
cept for the participants lost to follow-up. Follow-up was therefore
incomplete and analysis was not done by intention-to-treat. No
flow path of participants was documented. The authors consid-
ered both groups as comparable with respect to age and gender, as
well as to each measured variable at baseline.
Combined aerobic exercise and strength training trial in
myotonic dystrophy type 1
In the second myotonic dystrophy trial (Kierkegaard 2011), the
median value of the results of the six-minute walk test was used
to divide the 35 participants into two strata from which they were
divided into the training or the control group. The lots consisted
of folded pieces of paper with the name of the participant and
were drawn by a person not involved in any part of the study.
Since participants were recruited before randomisation, concealed
allocation procedures were applied. An intention-to-treat analy-
sis was applied. Three participants had missing data for perceived
exertion at baseline and one person in the control group did not
attend the measurement after the intervention but still completed
the questionnaires. There was no significant difference in sex or
age of participants between groups in the study; however, themean
muscular impairment scale (MIRS) grade was higher in the exer-
cise group, indicating that participants in the exercise group were
more severely impaired than participants in the control group. The
training group received a comprehensive group exercise training
programme, theywere also asked to perform an active 30minwalk
every week. The participants in the control group were advised
to live their normal lives and to maintain their degree of physical
activity during the study period. The degree of activity of both
groups was not objectively checked.
We ranked each criterion using the Cochrane ’Risk of bias’ tool.
The review authors’ judgements about each risk of bias item for
included studies are presented in Figure 1.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Quality of diagnostic criteria
This assessment took into account if and how diagnoses were veri-
fied. In the firstmyotonic dystrophy trial (Lindeman 1995), partic-
ipants were recruited via neurologists, physiatrists and the Dutch
association for neuromuscular diseases (Vereniging Spierziekten
Nederland) on clinical grounds and without genetic verification.
We therefore considered the quality of the diagnostic criteria
as inadequate. In the second myotonic dystrophy (type I) trial
(Kierkegaard 2011), the diagnosis was genetically confirmed in all
participants and the diagnostic criteria are therefore adequate.
In the dermatomyositis and polymyositis trial (Wiesinger 1998a),
all the participants had an established diagnosis of primary in-
flammatory muscle disease as defined by the established criteria
of Bohan and Peter, with a disease duration of at least six months
(Bohan 1975a; Bohan 1975b). In all participants, muscle biopsies,
electromyograms and laboratory studies had been performed to
establish the diagnosis. We therefore considered the quality of the
diagnostic criteria to be adequate.
In the FSHD trial (van der Kooi 2004), participants or a first-de-
gree relative had the associated deletion at chromosome 4 (Deidda
1996). The quality of the diagnosis was therefore adequate. In the
mitochondrial myopathy trial (Cejudo 2005) participants were
recruited from a larger group of patients followed at the university
hospital of Sevilla, Spain.Diagnosis was based on clinical andmus-
cle biopsy data. Biopsy findings were determined by biochemical
and histological techniques without genetic verification. One par-
ticipant in each group had only a probable diagnosis of mitochon-
drial myopathy. The quality of the diagnostic criteria is therefore
uncertain.
Quality of training programme
The training programmes of the first myotonic dystrophy (
Lindeman 1995), FSHD (van der Kooi 2004), mitochondrial
myopathy (Cejudo 2005) and dermatomyositis and polymyositis
(Wiesinger 1998a) trials fulfilled most of the minimum require-
ments as defined by the American College of Sports Medicine
(ACSM) Position Stand (Garber 2011). In the second myotonic
dystrophy type I trial (Kierkegaard 2011), the intervention con-
sisted of a comprehensive group exercise training programme sup-
ported by music. The author could not give the exact training
load of each strength training exercise as a percentage of repetition
maximum (RM) as it was not tested that way. However, all major
muscle groups were trained: arm, back, leg and abdominal muscles
(Kierkegaard 2011). The training scheme for the other strength
training trials was inadequate only with respect to the number of
muscle groups trained, as the ACSMrecommends eight to 10 exer-
cises of all themajor muscle groups. Only four muscle groups were
trained in the first myotonic dystrophy trial (Lindeman 1995),
two in the FSHD trial (van der Kooi 2004) and three in the mi-
tochondrial myopathy trial (Cejudo 2005).
All studies except the combined aerobic exercise and strength train-
ing inmyotonic dystrophy type I trial (Kierkegaard 2011), focused
on a limited number of muscle groups for reasons of effect evalu-
ation, safety and time restraints per training session.
In the dermatomyositis and polymyositis trial (Wiesinger 1998a),
the training frequency was only twice a week in the first two weeks,
but increased to three times a week in the remaining four weeks.
In the mitochondrial myopathy trial (Cejudo 2005), there was no
published information regarding supervision. In the other trials
(Kierkegaard 2011; Lindeman 1995; van der Kooi 2004), a phys-
iotherapist supervised training. A description of the training pro-
grammes is given in the Characteristics of included studies.
Effects of interventions
See: Summary of findings for the main comparison Strength
training compared to usual care for facioscapulohumeral muscular
dystrophy; Summary of findings 2 Aerobic exercise and strength
training compared to usual care for mitochondrial myopathy
We intended to combine trial results for appropriate pairings of
treatments by calculating a mean of the difference between their
effects using the Cochrane statistical package RevMan. Because we
could not obtain the original data for themitochondrial myopathy
(Cejudo 2005), dermatomyositis and polymyositis (Wiesinger
1998a) and myotonic dystrophy trials, we describe the results of
these trials as published in the article. We were unable to produce
MDs and 95% CIs for the myotonic dystrophy trial (Lindeman
1995) because of the matched pair design. We report the findings
of the study as given in the paper.
Primary outcome measure for strength training:
muscle strength, expressed in measures of static (ie.
isometric) or dynamic strength
Muscle strength was the primary outcome measure for the first
myotonic dystrophy (Lindeman 1995) and FSHD trials (van der
Kooi 2004). In the first myotonic dystrophy trial (Lindeman
1995), differences in muscle strength weremeasured isokinetically
on a dynamometer as maximum concentric knee torques at three
velocities, and isometrically as maximum voluntary contraction.
Knee torques of the myotonic dystrophy group did not show any
statistically significant difference between the training and control
groups, as found with a paired t-test. After 24 weeks, mean change
in isokinetic knee torque extension was 1.4 Nm (SD 8.2) for the
control group and 5.3 Nm (SD 12.9) for the training group, P
= 0.34. Mean change in isokinetic knee torque flexion was 3.7
Nm (SD 8.6) for the control group and 7.4 (SD 11.4) for the
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training group, P = 0.34 and mean change in maximum isometric
voluntary contractionwas 6.6Nm (SD11.0) for the control group
and 8.7 Nm (SD 14.71) for the training group, P = 0.67.
The primary outcome measure in the FSHD trial (van der Kooi
2004) was a change in maximum voluntary isometric strength of
the elbow flexors and ankle dorsiflexors, measured on a Quantita-
tive Muscle Assessment fixed myometry testing system. After 52
weeks the isometric strength of the elbow flexors did not differ
significantly between the training and non-training group, for the
right side the difference in the means was 0.54 kgF (95% CI -
0.38 to 1.46) (Analysis 2.1), with the better score being for the
training group. Dynamic strength was evaluated using the one-
repetition maximum (1RM), the weight a person can lift once,
but not twice, at a steady controlled pace through the full range of
joint motion. The 1RMof the elbow flexors showed a significantly
larger increase in the training group compared to the non-training
group (for the right side the difference in the means was 1.17 kg
(95% CI 0.18 to 2.16) (Analysis 2.2). Both strength measures of
the ankle dorsiflexors decreased significantly and markedly in all
treatment groups. This decrease was not influenced by training
(on the right side the difference in the means in maximum volun-
tary isometric contraction (MVIC) was 0.43 kgF (95% CI -1.62
to 2.48) (Analysis 2.3) more for the training group, in 1RM the
difference was -0.44 kg (95% CI -1.77 to 0.89) (Analysis 2.4) less
for the training group). Differences between groups for the left-
sided trained muscles did not materially differ from those for the
right side.
Muscle strength was a secondary outcome in the mitochondrial
myopathy trial (Cejudo 2005). In this trial, weight-lifting capacity
was measured as the heaviest weight that could be lifted through-
out the complete range of movement (1RM test). After the study
period, all participants showed increases in all 1RM tests. After
12 weeks, weight-lifting capacity did not differ significantly be-
tween the training and non-training group. The differences in
mean 1RM between groups were -5.00 kg (95% CI -14.71 to
4.71) less for the training group for the shoulder press exercise
(Analysis 3.1), 6.40 kg (95% CI -2.89 to 15.69) in favour of the
training group for the butterfly exercise (Analysis 3.2) and 7.30 kg
(95% CI -2.91 to 17.51) in favour of the training group for the
biceps curls exercise (Analysis 3.3).
Primary outcome measure for aerobic exercise
training: aerobic capacity, expressed in measures of
work capacity
This outcome was published in the mitochondrial myopathy trial
(Cejudo 2005) and was a primary outcome in the combined
aerobic exercise and strength training trial in myotonic dystro-
phy (Kierkegaard 2011). In the inflammatory muscle disease trial
(Wiesinger 1998a), no primary outcome measure was defined and
aerobic capacity was not measured. In the mitochondrial myopa-
thy trial (Cejudo 2005), work capacity was measured in a cycle
test and in the shuttle walking test. Endurance time was measured
in a submaximal cycling test at a constant workload of 70% of the
maximum power output achieved during the baseline incremen-
tal cycle test. After 12 weeks, the differences in mean time and
distance cycled till exhaustion and leg fatigue or breathlessness ex-
haustion differed significantly between groups. The differences in
mean time and distance cycled till exhaustion between groupswere
23.70 min (95% CI 2.63 to 44.77) (Analysis 3.4) and 9.70 km
(95% CI 1.51 to 17.89) (Analysis 3.5), respectively. The distance
walked until exhaustion was measured in the shuttle walking test
and was 78.00 mmore for the training group (95% CI -144.86 to
300.86) (Analysis 3.6). The primary outcome in the second my-
otonic dystrophy type I trial (Kierkegaard 2011) was the distance
walked in the six-minute walk test. A difference above or equal
to 6% in distance walked between the baseline measurement and
the measurement after the intervention period of 14 weeks was
considered as a minimally clinically important change. After 14
weeks, the differences in mean distance walked in the six-minute
walk test was 11.00 m (95% CI -66.92 to 88.92), in favour of the
training group (Analysis 4.1).
Secondary outcome measures for aerobic exercise or
strength training, or both
Aerobic capacity, expressed in measures of oxygen uptake
(ie. VO2 max)
This outcome was available for the mitochondrial myopathy (
Cejudo 2005) and inflammatory muscle disease trial (Wiesinger
1998a).
In the inflammatory muscle disease trial (Wiesinger 1998a), work
capacity was measured during an incremental cycle test on a cycle
ergometer. Maximal oxygen uptake (VO2max) was defined as the
highest O2 consumption obtained during the symptom-limited
exercise test. After six weeks, the difference inmean VO2 max (ml/
min/kg) was 14.6% higher for the training group (95% CI -0.96
to 30.16) (Analysis 1.1).
In themitochondrial myopathy trial (Cejudo 2005), VO2maxwas
noninvasively determined in a maximal incremental cycle exercise
test. After 12 weeks, the difference in mean VO2 max was 400 ml/
min (95% CI 61.97 to 861.97) in favour of the training group
(Analysis 3.9).
Muscle strength, expressed in measures of endurance or
fatigue
This outcome was published for the first myotonic dystrophy
(Lindeman 1995) and FSHD (van der Kooi 2004) studies. In the
myotonic dystrophy trial (Lindeman 1995), endurance was mea-
sured asmaximumduration of contraction at 80%ofMVICon an
isokinetic dynamometer. After 24 weeks, the difference in MVIC
for the control group was -7.4 s (SD 12.0) and for the training
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group 5.7 s (SD 17.0), P = 0.09. This difference was mainly due
to a decrease in endurance in the non-training group.
In the FSHD trial (van der Kooi 2004), muscle endurance was
expressed as a Force-Time Integral (FTI30) of a sustained 30 s
maximal isometric contraction measured on a Quantitative Mus-
cle Assessment fixed myometry testing system. After 52 weeks, the
FTI30 of the elbow flexors did not differ significantly between the
training andnon-training group.The FTI30 of the ankle dorsiflex-
ors decreased significantly and markedly in all treatment groups.
This decrease was not influenced by training (for the right side the
difference in the means was -1 kgF.s (95% CI -42 to 41). Changes
in FTI30 for the left-sided trained muscle groups did not differ
significantly from the right-sided results.
(Time-scored) functional assessments of muscle
performance
This outcome was available for all trials (Kierkegaard 2011;
Lindeman 1995; van der Kooi 2004; Wiesinger 1998a) except
the mitochondrial myopathy trial (Cejudo 2005). In the first my-
otonic dystrophy trial (Lindeman 1995), functional assessments
comprised the following time-scored activities: ascending and de-
scending stairs, rising from a chair, rising from supine, walking
50 m as fast as possible, and walking 6 m at natural speed. In the
inflammatory muscle disease trial (Wiesinger 1998a), the modi-
fied Functional Assessment Screening Questionnaire was used for
evaluating disability (Millard 1989) (Analysis 1.3).
In the FSHD trial (van der Kooi 2004) the functional tests con-
sisted of the assessment of a functional upper extremity grade and
functional lower extremity grade (Personius 1994), and the fol-
lowing timed-scored tasks: standing from lying supine, standing
from sitting, walking 30 feet (9.14 m), and climbing three stan-
dard stairs (Personius 1994). In the combined aerobic exercise and
strength training trial in myotonic dystrophy type 1 (Kierkegaard
2011), the timed-stands test, and the timed up-and-go test were
used for evaluation of effects of the exercises (Analysis 4.2; Analysis
4.3).
In all trials (Kierkegaard 2011; Lindeman 1995; van der Kooi
2004; Wiesinger 1998a), no differences between groups in func-
tional assessments were reported.
Quality of life
This outcome was assessed in the FSHD trial (van der Kooi 2004)
using the Sickness Impact Profile (SIP) and the Symptom-Check-
list (SCL-90-R). The mean total of the SIP and its subscales did
not demonstrate relevant or significant changes for either the train-
ing or non-training groups. In addition, for both groups the mean
SCL total did not change between the baseline and final visit.
In the mitochondrial myopathy trial (Cejudo 2005), the Notting-
ham Health Profile (NHP) questionnaire was used. Scores ranged
from 0 (no problem) to 100 (maximum problem). The MD in
overall mean score between both groupswas -9.80 (95%CI -25.70
to 6.14) (Analysis 3.7).
In the aerobic exercise and strength training trial in myotonic
dystrophy type I (Kierkegaard 2011), quality of life was measured
by the SF-36 Health Survey. The scores on all subscales of the SF-
36 did not demonstrate relevant or significant changes for either
the training or non-training group.
Parameters of muscle membrane permeability (serum
creatine kinase level, serum myoglobin level, serum aldolase
level)
This outcome was available for the first myotonic dystrophy trial
(Lindeman 1995), mitochondrial myopathy trial (Cejudo 2005)
and inflammatory muscle disease trial (Wiesinger 1998a). In the
myotonic dystrophy trial (Lindeman 1995), serummyoglobin lev-
els were assessed just before and one hour after the measurement
session at the baseline visit and at the final visit. Changes in serum
myoglobin activity one hour after a standardised test should reflect
changes in muscle fibre permeability due to muscle damage. The
mean rise in serum myoglobin levels did not differ significantly
between the training and the non-training group (-21.00 ng/l,
95% CI -48.35 to 6.35) (Analysis 3.8). In the inflammatory mus-
cle disease trial (Wiesinger 1998a), serum levels of creatine kinase
and aldolase were measured weekly on Monday after a weekend
recovery phase without exercise. There was no statistically signifi-
cant change in serum creatine kinase level and serum aldolase level
during the observation period either in the control group (mean -
13.9%, 95% CI -41.34 to 13.54) or in the training group (mean
-6%, 95% CI -22.66 to 10.66) (Analysis 1.2).
In the mitochondrial myopathy trial (Cejudo 2005), the authors
state that the participants’ serum creatine kinase levels remained
unaltered after the intervention period. However, data for the
serum creatine kinase level were not published. In the FSHD trial
(van der Kooi 2004), one participant stopped training because of
recurring, training-related muscle soreness and fatigue. A diagnos-
tic work-up revealed a mitochondrial myopathy as well as FSHD.
In the mitochondrial myopathy trial (Cejudo 2005), cancellations
of exercise sessions by participants happened because of muscle
soreness associated with the exercise activity. However, every par-
ticipant was able to tolerate the exercise training regimen without
complications. In the first myotonic dystrophy trial (Lindeman
1995), a few participants complained of muscle soreness and tran-
sient strength reduction after eight weeks. However, no signs of
muscle damage were found at the final visit after 24 weeks. In the
second myotonic dystrophy trial (Kierkegaard 2011), one person
had periods of atrial arrhythmia; however, this was not in connec-
tion with the training and the participant was allowed to complete
the study by a cardiologist. No other adverse effects were reported.
In all trials no other signs of overuse, such as a decline in strength
measures (Cejudo 2005; Lindeman 1995; van der Kooi 2004) or
training-related increase in pain or fatigue (van der Kooi 2004)
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were reported.
Pain
This outcome was available in both the FSHD (van der Kooi
2004) and mitochondrial myopathy trials (Cejudo 2005). In the
FSHD trial (van der Kooi 2004), 11 out of 34 participants in the
training group reported pain in the neck and shoulder region to
the physical therapist during home visits. Five people mentioned
a period with elbow complaints. However, the number of people
with neck-shoulder and elbow complaints did not differ between
treatment groups at baseline nor at the final visit. Moreover, the
number of participants with neck-shoulder and elbow complaints
slightly decreased in both groups. RR at the final visit was 1.02
(95%CI0.66 to 1.58) for neck-shoulder and1.82 (95%CI0.17 to
19.13) for elbow complaints in favour of the non-training group.
Although not formally quantified, the authors mentioned that
participants experienced no notable muscle soreness after training.
At the final visit, scores on the VAS for pain and the mean daily
rated pain scores did not demonstrate significant changes for either
group.
In the mitochondrial myopathy trial (Cejudo 2005), participants’
arm and leg myalgia was recorded by a simple questionnaire and
scored as mild, moderate or severe. Two people in the exercise
group and three people in the control group reported severe myal-
gia in arms and legs. Seven people in the exercise group and five
people in the control group reported moderate myalgia in arms
and legs. After the 12-week training programme no participants
in the exercise group and five participants in the control group still
reported symptoms of myalgia.
Experienced fatigue
In the FSHD trial (van der Kooi 2004), experienced fatigue was
measured by the subscale “fatigue severity” of the Checklist Indi-
vidual Strength (CIS-fatigue). At the final visit, the mean score on
the CIS-fatigue did not change significantly between the baseline
and final visit for either group. The mean daily rated fatigue score
of the participants in the training group slightly decreased, whereas
the score in the non-training group showed a small increase.
In the mitochondrial myopathy trial (Cejudo 2005), participants’
usual fatigability was recorded in a simple questionnaire and scored
as mild, moderate or severe. Three participants in the exercise
group and five participants in the control group reported severe
fatigue in arms and legs. At the end of the study period, no par-
ticipants in the exercise group and five participants in the control
group reported severe fatigue in arms and legs. Six participants
in the exercise group and two participants in the control group
reported moderate fatigue. After the intervention period, five par-
ticipants in the exercise group and two participants in the control
group still reported moderate fatigue.
Adverse events
There were no serious adverse effects related to strength or aerobic
training.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Aerobic exercise and strength training compared to usual care for mitochondrial myopathy
Patient or population: mitochondrial myopathy
Settings: unclear
Intervention: aerobic exercise and strength training
Comparison: usual care
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Usual care Aerobic exercise and
strength training
Difference in work ca-
pacity - mean time until
exhaustion in cycle test
electronically braked ergo
cycle
Follow-up: mean 12
weeks
The mean difference in
work capacity - mean
time until exhaustion in
cycle test in the control
groups was
-2.7 min
The mean difference in
work capacity - mean
time until exhaustion in
cycle test in the interven-
tion groups was
23.7 higher
(2.63 to 44.77 higher)
18
(1 study)
⊕⊕⊕©
moderate1
Difference in work ca-
pacity - mean distance
until exhaustion in cycle
test
electronically braked ergo
cycle
Follow-up: mean 12
weeks
The mean difference in
work capacity- mean dis-
tance until exhaustion in
cycle test in the control
groups was
-0.9 km
The mean difference in
work capacity- mean dis-
tance until exhaustion in
cycle test in the interven-
tion groups was
9.7 higher
(1.51 to 17.89 higher)
18
(1 study)
⊕⊕⊕©
moderate1
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 In this trial, clinical evaluators were not blinded, which may have led to an overestimation of the training effect on muscle strength and
aerobic capacity. Analysis in this trial was not by intention-to-treat.
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D I S C U S S I O N
Only six out of the 60 identified studies on the effect of training in
people with muscle disease used a randomised controlled design
(Cejudo 2005; Dawes 2006; Lindeman 1995; van der Kooi 2004;
Wiesinger 1998a; Kierkegaard 2011). The randomised controlled
strength training combined with aerobic exercise trial which com-
pared eight weeks of walking and strengthening exercises versus no
training in 20 participants with different muscle diseases (Dawes
2006) has been excluded because the outcome measures were not
presented separately for each different muscle disease. Moreover,
no specific details about the exercise programme were provided
and the risk of bias of the trial was judged as ’high’.
The strength training trial in FSHD participants (van der Kooi
2004) had minor methodological shortcomings. One of the main
secondary outcome measures, the 1RM strength measurement,
was performed by a physical therapist not blinded to the allocation
to training or non-training. The overall risk of bias was, therefore,
judged as ’low’.
The dermatomyositis and polymyositis trial (Wiesinger 1998a)
had several uncertainties regarding the generation of the randomi-
sation list, allocation concealment and blinding of the assessor. No
primary or secondary outcome measures were defined. The overall
risk of bias was, therefore, judged as ’unclear’.
In the myotonic dystrophy strength training trial (Lindeman
1995) diagnoses were not adequately verified. Furthermore, anal-
ysis was not by intention-to-treat partly due to the matched-pair
design. Because of these major methodological shortcomings, we
judged the overall risk of bias as ’unclear’.
In the mitochondrial myopathy trial (Cejudo 2005), clinical eval-
uators were not blinded, which may have led to an overestima-
tion of the training effect on muscle strength and aerobic capacity.
Analysis in this trial was not by intention-to-treat. The overall risk
of bias was therefore judged as ’unclear’.
Most differences in mean muscle strength outcomes (isometric,
dynamic and endurance) between groups in all trials showed
small, non-significant beneficial effects in favour of the training
groups. In the first myotonic dystrophy trial (Lindeman 1995),
only changes in the endurance measure (13.10 s longer maximum
duration of an isometric contraction (95% CI 2.20 to 24.00)) and
in the FSHD trial (van der Kooi 2004) only the dynamic strength
measure for the elbow flexors (concentric contraction with 1.20
kg heavier weight (95% CI 0.18 to 2.16)) reached statistical sig-
nificance. However, no adjustments were made for multiple com-
parisons.
The absent or limited positive effects of strength training on mus-
cle strength could reflect the inability of the diseased muscular
system to respond with normal neural and trophic adaptations to
the applied training stimuli. However, part of this lack of response
could be due to the specificity of the training (Lindeman 1995).
All adaptations to training are specific to the stimuli applied. Spe-
cific strength training essentially involves exercising the muscles
in the same manner as the expected use (Kraemer 2002). This
means that a training programme with dynamic exercises increases
dynamic strength more than isometric strength, and vice versa.
This phenomenon of specificity of training has implications for
the sensitivity of the outcome measures; for example, the positive
effect of a dynamic strength training programme may be captured
by using a dynamic evaluation technique, but might be missed us-
ing an isometric strength measure. The size of the carry-over effect
from, for example, dynamic strength to isometric strength cannot
be predicted and it may be that there is a diminished ability of the
diseased muscular system to transfer effects of a specific training
programme from one strength modality to another (van der Kooi
2004).
In the FSHD trial (van der Kooi 2004), training did not influence
strength of the ankle dorsiflexors, in contrast to the elbow flexors.
The authors thought that a difference in grade of muscle weakness
at baseline between elbow and ankle dorsiflexors might provide
the explanation for the difference in their response to training.
In this study elbow flexors were eligible for testing and training
when strength according to the MRC scale grade was three or
more, whereas ankle dorsiflexors were eligible when the muscles
moved the ankle joint in a position between dorsiflexion and plan-
tarflexion, which potentially includes MRC grades less than three
(Medical Research Council 1981). Therefore, pre-exercise weak-
ness might have been more severe in ankle dorsiflexors compared
to elbow flexors. In people with a muscle disease, it is assumed that
absolute gain inmuscle strength resulting from strength training is
probably related to pre-exercise muscle strength, and that severely
weakened muscles (< 10% of normal strength) may not be able to
improve. However, this widely reported assumption is based on
one published observation only (Milner-Brown 1988a).
In the mitochondrial myopathy trial (Cejudo 2005), the MD in
aerobic capacity as measured in a submaximal cycle test differed
significantly between the training and non-training group after the
study period. Participants in the training group cycled on average
23.70 min (95% CI 2.63 to 44.77) and 9.70 km longer (95% CI
1.51 to 17.89) than participants in the control group. The distance
walked in the shuttle walking test did not differ between groups.
This could be explained by the specificity of training, because
training consisted of cycling rather than walking exercises.
The timed-scored functional assessments did not demonstrate
any relevant or significant changes between treatment groups in
the two myotonic dystrophy trials (Lindeman 1995; Kierkegaard
2011), the dermatomyositis and polymyositis trial (Wiesinger
1998a) or the FSHD trial (van der Kooi 2004). This may be due
to the small number of muscle groups trained, the absent or lim-
ited effects on muscle strength, and the specificity of the training
stimuli applied.
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In all trials no signs of overuse were reported. This is of major
clinical importance because these findings do not support the no-
tion of increased risk of muscle strain in slowly progressive muscu-
lar dystrophies. However, adverse events were only mentioned in
general and not compared between groups. Only in the dermato-
myositis and polymyositis trial (Wiesinger 1998a), were serum
levels of enzymes mentioned for both groups. Moreover, several
participants in all trials experienced muscle soreness. An enhanced
liability for overwork weakness in more severely affected FSHD
patients cannot be excluded, because patients unable to walk in-
dependently were not included in the FSHD trial (van der Kooi
2004). Furthermore, all training studies, including the studies in-
cluded in this review, imposed a controlled strain for a relatively
short period. Hence, exertion of longer duration may still have an
undetermined effect on disease progression.
Based on the evidence of the five selected RCTs in this re-
view concerning myotonic dystrophy (Lindeman 1995) and my-
otonic dystrophy type I (Kierkegaard 2011), dermatomyositis and
polymyositis (Wiesinger 1998a), FSHD (van der Kooi 2004) and
mitochondrial myopathy (Cejudo 2005), people with these spe-
cific disorders can be advised that ’normal’ participation in sports
and work appears not to harm their muscles. Yet there is still insuf-
ficient evidence for general prescription of strength training and
aerobic exercise programmes in myotonic dystrophy, polymyosi-
tis and dermatomyositis and FSHD. Nevertheless, there is some
evidence for training effects in mitochondrial myopathy. Unfor-
tunately, no clearly defined exercise protocols can be drawn from
the current research evidence.
Evidence from non-randomised studies and other designs, such
as pre-post studies or case-control studies showed that aerobic
exercise training appears to be safe and effective in adults with
various muscle diseases and that strength training appears to be
safe and effective in adults with slowly progressive muscle diseases
(Cup 2007; Ansved 2008) but limitations in the design of these
studies prevent valid conclusions. The number of recent studies
lacking a randomised controlled design is striking. At least for the
relatively frequentmuscle diseases, one should aim for randomised
controlled training studies. Preferably, homogeneous groups of
people with the same muscle disease should be included. When
people with different neuromuscular disorders but with similar
distribution and severity of muscle weakness participate in the
same study, the data should also be presented for eachmajor type of
muscle disease separately to detect possible disease-specific trends.
Because we cannot pool the results of the trials in different muscle
diseases in this review, it is not possible to define the optimal
exercise duration for people with a specific muscle disease.
Specific diagnostic criteria should be given for all muscle diseases
included. Information on the severity of the muscle disease in
participants should also be presented so as to allow readers to
assess the generalisability of the results to other people with the
similar type and severity of muscle disease. In trials with a small
sample size, participants should be stratified for disease severity.
Another related characteristic that may influence outcome is the
level of activity (sedentary versus active) at baseline, because in
the healthy population untrained persons respond with higher
percentages and rates of gain in strength, compared to trained
individuals (Garber 2011). Activity level and change in activity
level for each participant should be monitored objectively during
the trial period, for example with an accelerometer.
Participants in an active training group may experience additional
non-specific benefits (that is,Hawthorne effects), for instance from
regular interaction with a skilled therapist, in contrast to those
in a non-treatment or usual care group. As it is well known that
suchHawthorne effectsmay affect outcome (Parsons 1974), future
studies should preferably have an appropriate control intervention
rather than ’no training’ in order to assess the specific benefits of
aerobic exercise and strength training. For example, the control
group might receive weekly counselling sessions with general in-
formation about exercise.
In strength training and aerobic exercise intervention studies, the
training programme should be described in detail, just as the pre-
scription of drugs would be. Authors should provide information
about the type(s) of exercises, the intensity (including progression
rate), frequency, duration per exercise session, the duration of the
entire programme, as well as the trained muscle groups, and the
supervision of training.
The recommendations from the ACSM Position Stand on ’The
recommended quantity and quality of exercise for developing and
maintaining cardiorespiratory and muscular fitness, and flexibility
in healthy adults’ (Garber 2011) can be used as requirements for
an effective, safe and individualised exercise prescription, taking
into account the pre-training level of fitness. The ACSM recom-
mendations were almost all adhered to by most of the included
and excluded studies in this review. The only criterion that was
rarely met was that eight to 10 major muscle groups should be
exercised in strength training programmes. This is probably partly
due to limitations in time available to evaluate the effects of train-
ing by multiple assessments covering the different outcome mea-
sures. In addition, expenses for (adjusted) training equipment can
be high. Thirdly, investigators were perhaps too cautious in order
not to strain participants too much. Moreover, strength training
for fewer than eight muscle groups could be adequate in people
with a muscle disease, who are generally untrained.
More studies that evaluate the level of basic muscle function and
aerobic capacity are needed on the effects of aerobic exercise and
strength training programmes in people with specific muscle dis-
eases. There are well-validated outcome measures that are able
to assess positive and, at least equally important, negative effects
on the diseased muscular system. The expertise to deliver train-
ing programmes in healthy individuals is already present in sports
medicine and experts in exercise physiology should be consulted.
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If strength training and aerobic exercise training programmes
prove to be effective for people with a muscle disease, we can then
aim to develop and evaluate programmes adjusted to each differ-
ent muscle disease. In people with muscular disorders, combina-
tions of muscle weakness, fatigue, pain and difficulty exercising
can all lead to reduced physical activity and a sedentary lifestyle
(McDonald 2002). Physical inactivity negatively impacts quality
of life and health outcomes (McDonald 2002).
In healthy young adults, in the elderly, and in cardiac patients, in-
creasing physical activity and participation by comprehensive ex-
ercise programmes incorporating aerobic activities, strength train-
ing and flexibility exercises has been shown to reduce the risk of
several chronic diseases (for example, coronary heart disease, obe-
sity, diabetes and osteoporosis) (Garber 2011). Therefore, indica-
tors of chronic disease risk such as blood pressure, resting heart
rate, body mass, glucose tolerance and bone density could be use-
ful as additional outcome measures (Kilmer 2002), although little
is known about the risks of comorbidity in people with a muscle
disease. Cost-benefit analyses are only relevant if the benefit of
training is much higher than studies have shown so far.
In summary, the authors’ recommendations for future studies are
as follows.
• Participants with different muscle disorders can participate
in one study, but data should be presented for each major type of
muscle disease separately.
• Randomised controlled comparisons should be made with
participants having the same muscle disease. The effect of
training in people with a muscle disease should be compared to a
non-exercising control group of people with the same muscle
disease and not to healthy individuals, or to contralateral non-
exercised limbs.
• An appropriate placebo intervention is recommended in
order to measure exercise-specific benefits.
• Stratified randomisation is strongly advised with regard to
disease severity, particularly in studies with a small sample size. It
should also be considered for pre-training level of activity
(sedentary versus active), particularly in aerobic intervention
studies.
• The following aspects of the training intervention should be
specified: type(s) of exercise training, intensity and progression
rate, frequency, duration per exercise session and of the entire
programme, trained muscle groups, and supervision of training.
Duration of the training intervention should be at least six weeks.
• Outcomes should at least include measures of muscle
function (for example, strength, endurance measured by the
maximum duration of contraction) and aerobic capacity (for
example, work capacity measured by an incremental cycle test),
and functional assessments such as a six-minute walk test.
Researchers should be aware of the specificity of training effects
in their choice of outcome measures. The following evaluations
are strongly advised: measures of quality of life, pain and
experienced fatigue.
• Outcomes assessors should be blinded to interventions, to
avoid measurement bias.
• Activity level of participants in the control group should be
monitored objectively in order to assess the specific benefits of
aerobic exercise and strength training exercise.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the evidence from five RCTs in this review, moderate-in-
tensity strength training in myotonic dystrophy (Lindeman 1995)
and FSHD (van der Kooi 2004), aerobic exercise therapy in der-
matomyositis and polymyositis (Wiesinger 1998a) and a combi-
nation of strength and aerobic exercise training in myotonic dys-
trophy type I (Kierkegaard 2011) show no harm, but there is in-
sufficient evidence to conclude that they offer benefit. A combi-
nation of aerobic exercise and strength training in mitochondrial
myopathy shows no harm and could be beneficial for aerobic ca-
pacity (Cejudo 2005). The small number of included studies and
limitations in study design of the other studies prevent general
conclusions in other muscle diseases.
Implications for research
There is a need for more research to establish whether strength
training and aerobic exercise training is beneficial in all forms of
muscle disease, and to define the optimal exercise programmes for
people with a muscle disease.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cejudo 2005
Methods Parallel group RCT
Participants 20 adults with mitochondrial myopathy, diagnosed on the basis of clinical, familial and
muscle biopsy data
Interventions Strength training and aerobic exercise training versus no training
Type of training and exercise
Endurance bicycle training, dynamic isotonic with weights
Intensity
Aerobic training: individualised work rate, 30 min leg exercise on an ergo cycle, 70% of
the peakwork rate; strength training: one set dynamic and isotonic of 10 to 15 repetitions
at 50% 1RM load, to 2 or 3 sets. Adjustments on workload changed every 2 weeks
Frequency
3 times/week
Duration
Session: approximately 60 min. Programme: 24 weeks
Muscle groups
Shoulder, upper back, arm, pectoralis major, biceps brachii and brachialis muscles
Supervision
Supervised training programme by specialised nurses and a physiatrist specialist in a
rehabilitation unit on an outpatient basis
Outcomes Primary: exercise capacity - expressed in measures of oxygen uptake (ie. VO2 max),
endurance time and distance walked in the shuttle walking test. Secondary outcomes
were: peripheral muscle strength (1RMtest), quality of life, symptoms ofmyalgia, cramps
and fatigability and functional exercise capacity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Patients were randomly assigned to a training group or
control group”
Comment: no published information on the sequence genera-
tion. The author (Cejudo) informed us that patients were ran-
domly assigned according to a computer generated randomisa-
tion list
Allocation concealment (selection bias) Unclear risk Quote: “Patients were randomly assigned to a training group or
control group”
Comment: no published information on the allocation conceal-
ment. The author (Cejudo) informed us that patients were ran-
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Cejudo 2005 (Continued)
domly assigned according to a computer generated randomisa-
tion list
Blinding (performance bias and detection
bias)
All outcomes
High risk Comment: no published information on the blinding of the out-
come assessors and personnel. The author (Cejudo) told us that
the evaluators knew to which group each patient was assigned
Incomplete outcome data (attrition bias)
All outcomes
High risk Quote: “...one patient in each group failed to finish the study
for personal reasons”
Comment: baseline outcome data assessed, but not available for
these patients. So 1/10 missing from intervention group and 1/
10 missing from control group
Selective reporting (reporting bias) High risk No primary and secondary outcome(s) defined in the article
Other bias Low risk No risk of bias from other sources detected
Kierkegaard 2011
Methods Evaluator blind, parallel group RCT
Participants 35 adults with myotonic dystrophy type 1, genetically confirmed
Interventions Strength training and aerobic exercise training versus no training
Type of training and exercise
Strength training, aerobic exercise, balance exercises
Intensity
Strength exercises for arm, leg, back and abdominal muscles 16-20 repetitions, for 6-
7 min, balance exercises for 3-4 min, aerobic activities for 11-12 min at 60-80% of
maximum heart rate. Once a week a 30-min brisk walk
Frequency
2 times/week and once a week a brisk walk
Duration
Session: 60 min and a 30-min walk. Programme: 14 weeks
Muscle groups
Arm, leg, back and abdominal muscles
Supervision
All sessions were supervised by a specialised physiotherapist
Outcomes Primary: distance walked in the 6-min walk test
Secondary: timed-stands test, timed up-and-go test
Notes Participants were stratified before randomisation by their results in the 6-min walk test
Risk of bias
Bias Authors’ judgement Support for judgement
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Kierkegaard 2011 (Continued)
Random sequence generation (selection
bias)
Low risk Quote: “The lots were drawn by a person who
was not involved in any other part of the study”
Allocation concealment (selection bias) Low risk Quote: “Participants were recruited before ran-
domisation”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “Data was collected before and after the
intervention by two independent experienced
physiotherapists, blinded to group allocation and
each assessing the same participants on both oc-
casions”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “one person in the control group did not
attend the data collection after the intervention”
Selective reporting (reporting bias) Low risk No evidence found for selective reporting
Other bias Low risk No risk of bias from other sources detected
Lindeman 1995
Methods Evaluator blind, matched-control RCT
Participants 36 adults with myotonic dystrophy (2 congenital form, 34 classical adult type), diagnosis
not verified
Interventions Strength training versus no training
Type of training and exercise
Dynamic strength training with weights
Intensity
Individualised progressive overload, 3 sets from 25 repetitions at 60% of 1RM, via 15
repetitions at 70%, to 10 repetitions at 80%
Frequency
3 times/week
Duration
Session: within 30 min. Programme: 24 weeks
Muscle groups
Knee extensors and flexors, hip extensors and abductors
Supervision
Supervised home training programme
Outcomes Primary: muscle strength by isokinetically measured knee torques and isometrically as
MVIC.Main secondary outcomeswere: endurance bymaximumduration of contraction
at 80% of MVIC, functional performance by timed motor performance tests and by
questionnaires. Serum myoglobin levels to detect changes in muscle fibre membrane
permeability
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Lindeman 1995 (Continued)
Notes Participantswerematchedbased onmuscle strength (knee extension torque/bodyweight)
and on performance in a stair-climbing test. Only complete pairs were analysed
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Comment: there was no published informa-
tion on the sequence generation but the au-
thor (Lindeman) informed us that 2 indepen-
dent persons drew a sealed lot per matched
pair and allocated it by tossing a coin to the
training or non-training group
Allocation concealment (selection bias) Low risk Comment: there was no published informa-
tion on themethod of allocation concealment
but the author (Lindeman) informed us that
2 independent persons allocated the training,
after tossing the coin, to the training or non-
training group
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “observers of the outcome measure-
ments were blinded for treatment allocation”
Comment: approximately 20% of the my-
otonic dystrophy participants revealed infor-
mation to the clinical evaluators that resulted
in unblinding during the course of the trial
Incomplete outcome data (attrition bias)
All outcomes
High risk 3 of the initially 36 randomised participants
withdrew before disclosure of treatment allo-
cation. The 33 participants starting the trial
made 15 matched pairs. During the trial 1
person dropped out. Because of the matched
pair design only complete pairs were analysed,
therefore eventually 28 of the initial 36 ran-
domised participants were analysed. Follow-
up was therefore incomplete and analysis was
not by intention-to-treat. However, the flow
path of participants was well documented
Selective reporting (reporting bias) Low risk No evidence found for selective reporting
Other bias Low risk No risk of bias from other sources detected
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van der Kooi 2004
Methods Evaluator blind, parallel group, RCT
Participants 65 adults with FSHD, genetically confirmed
Interventions Strength training versus no training (and as add-on in a double blind randomised con-
trolled design albuterol or placebo)
Type of training and exercise
Dynamic and isometric strength training with weights
Intensity
Individualised progressive overload, 2 sets dynamic from 10 repetitions at 10RM, via 8
repetitions at 8RM, to 5 repetitions at 5RM, and 30s isometric with same weight
Frequency
3 times/week
Duration
Session: Within 30 min. Programme: 52 weeks
Muscle groups
Elbow flexors, ankle dorsiflexors
Supervision
Supervised home training programme
Outcomes Primary: difference in muscle strength of elbow flexors and ankle dorsiflexors after 52
weeks using the MVIC. Main secondary outcomes were muscle endurance (MVIC
Force-Time Integral) and dynamic muscle strength (1RM). Other measures included
functional tests and timed motor performance tasks
Notes Outcomes are presented for the 4 treatment groups (ie. the 4 combinations of training
versus non-training, and albuterol versus placebo). Effect sizes are presented by inter-
vention as well
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “...participants were randomly assigned
to one of the four treatment groups according
to a computer generated randomisation list”
Allocation concealment (selection bias) Unclear risk Quote: “informationon the assignment to train-
ing or non-training was disclosed to the partic-
ipants by the physical therapist”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Quote: “The RM measurements were per-
formed by the physical therapist, who was not
blinded for the allocation to training or non-
training, as this specific measurement carried
too great a risk of unblinding the clinical evalu-
ator”
Comment: adequate although one of the main
secondary outcome measures, the 1RM mea-
28Strength training and aerobic exercise training for muscle disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
van der Kooi 2004 (Continued)
surement for assessing dynamic strength, was
performed by the physical therapist, who super-
vised the training, and was therefore not blinded
to the allocation to training or non-training.
Unblinding during the trial was adequately reg-
istered. Allocation to training or non-training
was unmasked in 3 cases, due to unintentional
remarks
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “One patient stopped training because
of recurring, training-related muscle soreness
and fatigue. Four participants stopped using
their study medication because of side effects.
Data for the participants who discontinued an
intervention were analysed in the assigned treat-
ment group”
Comment: complete follow-up of all partici-
pants
Selective reporting (reporting bias) Low risk No evidence found for selective reporting
Other bias Low risk No risk of bias from other sources detected
Wiesinger 1998a
Methods Parallel group RCT
Participants 9 adults with dermatomyositis and 5 adults with polymyositis
Diagnosis of primary inflammatory muscle disease was defined by the criteria of Bohan
and Peter
Interventions Aerobic exercise training versus no training
Type of training and exercise
Endurance bicycle training, endurance step aerobics
Intensity
Bicycle training: 30min, slowly increased on an individual basis. Resistance was increased
until a heart rate of 60% of maximum. Step aerobics: 30 min
Frequency
During the first 2 weeks, twice weekly, during the remaining 4 weeks, 3 times weekly
Duration
Session: 60 min. Programme: 6 weeks
Muscle groups
Not applicable
Supervision
Supervised by a physiotherapist
Outcomes No primary outcome or secondary outcomes defined. Study outcomes: activities of
daily living score, peak isometric torque of knee extensors and hip flexors, peak oxygen
consumption and creatine kinase and aldolase levels
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Wiesinger 1998a (Continued)
Notes Outcomes are not presented separately for the dermatomyositis and polymyositis patients
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “Distinct randomisation lists were used”. Comment:
there was no information about the generation of the list. It is
not clear what is meant by “distinct randomisation lists”
Allocation concealment (selection bias) Unclear risk Comment: there was no published information on the method
of allocation concealment
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Quote: “Muscle strength assessments were carried out by the
same person who was unaware of the group to which the indi-
vidual patients belonged”. Comment: there was no published
information about blinding of the assessor of the other measure-
ments
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: complete follow-up of all participants
Selective reporting (reporting bias) High risk Comment: no primary or secondary outcomes are defined
Other bias Low risk No risk of bias from other sources detected. Outcomes are not
presented for dermatomyositis and polymyositis separately
MVIC: maximum voluntary isometric strength
RCT: randomise controlled trial
RM: repetition maximum
VO2 max: maximal oxygen uptake
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abramson 1952 Not a RCT
Aitkens 1993 Not a RCT. Exercised versus non-exercised control limb (randomly assigned) and patients versus healthy
volunteers
Aldehag 2005 Not a RCT
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(Continued)
Alexanderson 1999 Pilot study. Not a RCT
Alexanderson 2000 Extension of a pilot study Alexanderson 1999. Not a RCT
Alexanderson 2007 Not a RCT
Arnardottir 2003 Not a RCT
Chung 2007 No non-exercising control group
Dastmalchi 2007 Not a RCT
Dawes 2006 Excluded because of serious insufficiencies in the study design
De Lateur 1979 Not a RCT. Exercised versus non-exercised control limb (randomly assigned)
Escalante 1993 Not a RCT
Florence 1984a Not a RCT
Florence 1984b Not a RCT
Fowler 1965 Not a RCT. Exercise combined with medication
Heikkila 2001 Not a RCT. Training programme duration of 3 weeks
Hicks 1989 Not a RCT. Training programme duration of 1 month
Hoberman 1955 Not a RCT. 3 drugs added to a comprehensive regimen of therapies, including breathing and resistive exercises
Jeppesen 2006 Not a RCT
Jeppesen 2009a Not a RCT
Johnson 2007 Not a RCT
Johnson 2009 Not a RCT
Kelm 2001 Not a RCT
Kilmer 1994 Not a RCT. Exercised versus non-exercised control limb (randomly assigned) and patients versus healthy
volunteers
Kilmer 2005 Not a RCT
Lenman 1959 Not a RCT. Training programme duration for participants with muscle disorders ranged from approximately
1 to 21 months
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(Continued)
Mate-Munoz 2007 Not a RCT
McCartney 1988 Not a RCT. Exercised versus non-exercised control limb (randomly assigned)
Mielke 1990 Not a RCT
Milner-Brown 1988a Not a RCT. Training programme duration for participants with muscle disorders ranged from approximately
2 to 48 months
Milner-Brown 1988b Not a RCT. Intervention is not training versus non-training, but training added to electric stimulation or
electric stimulation only in 1 limb versus a non-stimulated, non-exercised control limb
Milner-Brown 1990 Not a RCT. Intervention is not training versus no training, but amitriptyline added to strength training
Murphy 2008 Not a RCT
Na 1996 Not a RCT. Intervention is not training versus non-training, but training and daily quinine sulfate
Nader 2010 Not a RCT
Olsen 2005 Not a RCT
Omori 2010 Not a RCT
Orngreen 2005 Not a RCT
Scott 1981 A RCT that makes a comparison between 2 different training regimes. No comparison of training versus
non-training participants
Siciliano 2000 Not a RCT
Spector 1997 Not a RCT
Sunnerhagen 2004 Not a RCT
Sveen 2007 Not a RCT
Sveen 2008 Not a RCT
Taivassalo 1998 Not a RCT
Taivassalo 1999 Not a RCT
Taivassalo 2001 Not a RCT
Taivassalo 2006 Not a RCT
Tollbäck 1999 Not a RCT. Exercised versus non-exercised control limb (randomly assigned)
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Trenell 2006 Not a RCT
Varju 2003 Not a RCT. Training programme duration of 3 weeks
Vignos 1966 Not a RCT.
Wiesinger 1998b A non-randomised extension of a RCT (Wiesinger 1998a)
Wright 1996 Not a RCT
Yildirim 2007 Not a RCT
RCT: randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Alexanderson 2009
Methods RCT
Participants Patients with recent onset dermatomyositis and polymyositis
Interventions A resistive home exercise program versus no training
Outcomes -
Notes The study will be submitted early 2012
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
Jansen 2010
Trial name or title Physical training in boys with Duchenne Muscular Dystrophy: the protocol of the No Use is Disuse study
This study consists of two separate studies.
Study 1 ”Dynamic leg and arm training for ambulant and recently wheelchair-dependent boys with DMD
Study 2 “Functional training with arm support for boys with DMD who have been confined to a wheelchair
for several years”
Methods Study 1: an explorative RCT with multiple baseline measurements
Study 2: a within-group repeated measurements design
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Jansen 2010 (Continued)
Participants Study 1: 30 boys with a DNA-established diagnosis of DMD
Study 2: 10 boys with a DNA-established diagnosis of DMD already confined to a wheelchair for several
years
Interventions Study 1: 6-months physical training during which boys train their legs and arms with active or assisted cycling
training equipment
Study 2: 6-months physical training program consisting of 1) computer-assisted training and 2) functional
training with an arm support
Outcomes Study 1: the primary study outcomes are muscle endurance and functional abilities, assessed with a 6-min
bicycle test and the Motor Function Measure
Study 2: the primary study outcome is functional abilities of the upper extremity, assessed with the Action
Research Arm Test
Starting date -
Contact information m.jansen@reval.umcn.nl
Notes The study will finish at the end of 2010 and results are expected in 2012
Voet 2010
Trial name or title Effect of aerobic exercise training and cognitive behavioural therapy on reduction of chronic fatigue in patients
with facioscapulohumeral dystrophy: protocol of the FACTS-2-FSHD trial
Methods A multicentre, assessor-blinded, RCT
Participants 75 adults with FSHD with severe chronic fatigue (CIS-fatigue ≥ 35)
Interventions Participants will be randomised to one of 3 groups:
• a control group (usual care alone, consisting of no therapy at all or occasional (conventional) physical
therapy)
• CBT plus usual care
• AET, compromising cycle exercises for 4 months plus usual care
After an intervention period of 16 weeks and a follow-up of 3 months, the third (control) group will be
randomised to either AET or CBT (approximately 7 months after inclusion)
Outcomes Primary outcome measure: experienced fatigue as measured with the CIS. Outcomes will be assessed at
baseline, immediately post intervention and at 3 and 6 months follow-up
Starting date January 2009
Contact information N.Voet@reval.umcn.nl
Notes The study will finish at the end of 2012 and results are expected in 2013
AET: aerobic exercise therapy
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CBT: cognitive behavioural therapy
CIS: Checklist Individual Strength
DMD: Duchenne muscular dystrophy
FSHD: facioscapulohumeral dystrophy
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Aerobic exercise training versus control in polymyositis and dermatomyositis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Aerobic capacity 1 14 Mean Difference (IV, Fixed, 95% CI) 14.6 [-0.96, 30.16]
2 Creatine kinase and aldolase
serum level
1 14 Mean Difference (IV, Fixed, 95% CI) 7.9 [-24.20, 40.00]
3 Functional assessment -
functional assessment screening
questionnaire.
1 14 Mean Difference (IV, Fixed, 95% CI) 17.6 [-5.58, 40.78]
Comparison 2. Strength training versus control in facioscapulohumeral muscular dystrophy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Muscle strength elbow flexors -
maximum voluntary isometric
contraction
1 65 Mean Difference (IV, Fixed, 95% CI) 0.54 [-0.38, 1.46]
2 Muscle strength elbow flexors -
dynamic strength
1 65 Mean Difference (IV, Fixed, 95% CI) 1.17 [0.18, 2.16]
3 Muscle strength ankle
dorsiflexors - maximum
isometric voluntary contraction
1 65 Mean Difference (IV, Fixed, 95% CI) 0.43 [-1.62, 2.48]
4 Muscle strength ankle
dorsiflexors - dynamic strength
1 65 Mean Difference (IV, Fixed, 95% CI) -0.44 [-1.77, 0.89]
Comparison 3. Aerobic exercise and strength training versus control in mitochondrial myopathy
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Muscle strength shoulder press
- maximum dynamic isotonic
voluntary contraction
1 18 Mean Difference (IV, Fixed, 95% CI) -3.00 [-14.71, 4.71]
2 Muscle strength butterfly -
maximum dynamic isotonic
voluntary contraction
1 18 Mean Difference (IV, Fixed, 95% CI) 6.4 [-2.89, 15.69]
3 Muscle strength biceps curls -
maximum isotonic dynamic
voluntary contraction
1 18 Mean Difference (IV, Fixed, 95% CI) 7.3 [-2.91, 17.51]
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4 Work capacity - mean time until
exhaustion in cycle test
1 18 Mean Difference (IV, Fixed, 95% CI) 23.7 [2.63, 44.77]
5 Work capacity - mean distance
until exhaustion in cycle test
1 18 Mean Difference (IV, Fixed, 95% CI) 9.70 [1.51, 17.89]
6 Work capacity - mean distance
walked until exhaustion in
shuttle walking test
1 18 Mean Difference (IV, Fixed, 95% CI) 78.0 [-144.86, 300.
86]
7 Quality of life 1 18 Mean Difference (IV, Fixed, 95% CI) -9.8 [-25.74, 6.14]
8 Myoglobin 1 30 Mean Difference (IV, Fixed, 95% CI) -21.0 [-48.35, 6.35]
9 VO2 max in maximal
incremental cycle exercise test
1 18 Mean Difference (IV, Fixed, 95% CI) 400.0 [-61.97, 861.
97]
Comparison 4. Aerobic exercise and strength training versus control in myotonic dystrophy type 1
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Distance walked in 6-minute
walk test
1 35 Mean Difference (IV, Fixed, 95% CI) 11.0 [-66.92, 88.92]
2 Timed-stands test 1 35 Mean Difference (IV, Fixed, 95% CI) -1.0 [-6.76, 4.76]
3 Timed-up-and-go tests 1 35 Mean Difference (IV, Fixed, 95% CI) -0.5 [-1.86, 0.86]
Analysis 1.1. Comparison 1 Aerobic exercise training versus control in polymyositis and dermatomyositis,
Outcome 1 Aerobic capacity.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 1 Aerobic exercise training versus control in polymyositis and dermatomyositis
Outcome: 1 Aerobic capacity
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[ml/min/kg] N Mean(SD)[ml/min/kg] IV,Fixed,95% CI IV,Fixed,95% CI
Wiesinger 1998a 7 12 (12.44) 7 -2.6 (16.93) 100.0 % 14.60 [ -0.96, 30.16 ]
Total (95% CI) 7 7 100.0 % 14.60 [ -0.96, 30.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.066)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours control Favours training
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Analysis 1.2. Comparison 1 Aerobic exercise training versus control in polymyositis and dermatomyositis,
Outcome 2 Creatine kinase and aldolase serum level.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 1 Aerobic exercise training versus control in polymyositis and dermatomyositis
Outcome: 2 Creatine kinase and aldolase serum level
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
Wiesinger 1998a 7 -6 (22.49) 7 -13.9 (37.04) 100.0 % 7.90 [ -24.20, 40.00 ]
Total (95% CI) 7 7 100.0 % 7.90 [ -24.20, 40.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours training Favours control
Analysis 1.3. Comparison 1 Aerobic exercise training versus control in polymyositis and dermatomyositis,
Outcome 3 Functional assessment - functional assessment screening questionnaire..
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 1 Aerobic exercise training versus control in polymyositis and dermatomyositis
Outcome: 3 Functional assessment - functional assessment screening questionnaire.
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Wiesinger 1998a 7 20.5 (10.87) 7 2.9 (29.34) 100.0 % 17.60 [ -5.58, 40.78 ]
Total (95% CI) 7 7 100.0 % 17.60 [ -5.58, 40.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 2.1. Comparison 2 Strength training versus control in facioscapulohumeral muscular dystrophy,
Outcome 1 Muscle strength elbow flexors - maximum voluntary isometric contraction.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 2 Strength training versus control in facioscapulohumeral muscular dystrophy
Outcome: 1 Muscle strength elbow flexors - maximum voluntary isometric contraction
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2004 34 -0.06 (1.93) 31 -0.6 (1.87) 100.0 % 0.54 [ -0.38, 1.46 ]
Total (95% CI) 34 31 100.0 % 0.54 [ -0.38, 1.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours control Favours training
Analysis 2.2. Comparison 2 Strength training versus control in facioscapulohumeral muscular dystrophy,
Outcome 2 Muscle strength elbow flexors - dynamic strength.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 2 Strength training versus control in facioscapulohumeral muscular dystrophy
Outcome: 2 Muscle strength elbow flexors - dynamic strength
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2004 34 2.56 (2.09) 31 1.39 (1.97) 100.0 % 1.17 [ 0.18, 2.16 ]
Total (95% CI) 34 31 100.0 % 1.17 [ 0.18, 2.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours control Favours training
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Analysis 2.3. Comparison 2 Strength training versus control in facioscapulohumeral muscular dystrophy,
Outcome 3 Muscle strength ankle dorsiflexors - maximum isometric voluntary contraction.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 2 Strength training versus control in facioscapulohumeral muscular dystrophy
Outcome: 3 Muscle strength ankle dorsiflexors - maximum isometric voluntary contraction
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2004 34 -1.13 (4.28) 31 -1.56 (4.16) 100.0 % 0.43 [ -1.62, 2.48 ]
Total (95% CI) 34 31 100.0 % 0.43 [ -1.62, 2.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours control Favours training
Analysis 2.4. Comparison 2 Strength training versus control in facioscapulohumeral muscular dystrophy,
Outcome 4 Muscle strength ankle dorsiflexors - dynamic strength.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 2 Strength training versus control in facioscapulohumeral muscular dystrophy
Outcome: 4 Muscle strength ankle dorsiflexors - dynamic strength
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
van der Kooi 2004 34 -1.5 (2.68) 31 -1.06 (2.78) 100.0 % -0.44 [ -1.77, 0.89 ]
Total (95% CI) 34 31 100.0 % -0.44 [ -1.77, 0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
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Analysis 3.1. Comparison 3 Aerobic exercise and strength training versus control in mitochondrial
myopathy, Outcome 1 Muscle strength shoulder press - maximum dynamic isotonic voluntary contraction.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 3 Aerobic exercise and strength training versus control in mitochondrial myopathy
Outcome: 1 Muscle strength shoulder press - maximum dynamic isotonic voluntary contraction
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cejudo 2005 9 5.7 (11) 9 10.7 (10) 100.0 % -5.00 [ -14.71, 4.71 ]
Total (95% CI) 9 9 100.0 % -5.00 [ -14.71, 4.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 3.2. Comparison 3 Aerobic exercise and strength training versus control in mitochondrial
myopathy, Outcome 2 Muscle strength butterfly - maximum dynamic isotonic voluntary contraction.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 3 Aerobic exercise and strength training versus control in mitochondrial myopathy
Outcome: 2 Muscle strength butterfly - maximum dynamic isotonic voluntary contraction
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cejudo 2005 9 7 (9) 9 0.6 (11) 100.0 % 6.40 [ -2.89, 15.69 ]
Total (95% CI) 9 9 100.0 % 6.40 [ -2.89, 15.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 3.3. Comparison 3 Aerobic exercise and strength training versus control in mitochondrial
myopathy, Outcome 3 Muscle strength biceps curls - maximum isotonic dynamic voluntary contraction.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 3 Aerobic exercise and strength training versus control in mitochondrial myopathy
Outcome: 3 Muscle strength biceps curls - maximum isotonic dynamic voluntary contraction
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cejudo 2005 9 8 (10) 9 0.7 (12) 100.0 % 7.30 [ -2.91, 17.51 ]
Total (95% CI) 9 9 100.0 % 7.30 [ -2.91, 17.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.40 (P = 0.16)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 3.4. Comparison 3 Aerobic exercise and strength training versus control in mitochondrial
myopathy, Outcome 4 Work capacity - mean time until exhaustion in cycle test.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 3 Aerobic exercise and strength training versus control in mitochondrial myopathy
Outcome: 4 Work capacity - mean time until exhaustion in cycle test
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cejudo 2005 9 21 (28) 9 -2.7 (16) 100.0 % 23.70 [ 2.63, 44.77 ]
Total (95% CI) 9 9 100.0 % 23.70 [ 2.63, 44.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.20 (P = 0.027)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 3.5. Comparison 3 Aerobic exercise and strength training versus control in mitochondrial
myopathy, Outcome 5 Work capacity - mean distance until exhaustion in cycle test.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 3 Aerobic exercise and strength training versus control in mitochondrial myopathy
Outcome: 5 Work capacity - mean distance until exhaustion in cycle test
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cejudo 2005 9 8.8 (11) 9 -0.9 (6) 100.0 % 9.70 [ 1.51, 17.89 ]
Total (95% CI) 9 9 100.0 % 9.70 [ 1.51, 17.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.32 (P = 0.020)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 3.6. Comparison 3 Aerobic exercise and strength training versus control in mitochondrial
myopathy, Outcome 6 Work capacity - mean distance walked until exhaustion in shuttle walking test.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 3 Aerobic exercise and strength training versus control in mitochondrial myopathy
Outcome: 6 Work capacity - mean distance walked until exhaustion in shuttle walking test
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cejudo 2005 9 95 (222) 9 17 (259) 100.0 % 78.00 [ -144.86, 300.86 ]
Total (95% CI) 9 9 100.0 % 78.00 [ -144.86, 300.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
-200 -100 0 100 200
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Analysis 3.7. Comparison 3 Aerobic exercise and strength training versus control in mitochondrial
myopathy, Outcome 7 Quality of life.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 3 Aerobic exercise and strength training versus control in mitochondrial myopathy
Outcome: 7 Quality of life
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cejudo 2005 9 -8.3 (16.8) 9 1.5 (17.7) 100.0 % -9.80 [ -25.74, 6.14 ]
Total (95% CI) 9 9 100.0 % -9.80 [ -25.74, 6.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 3.8. Comparison 3 Aerobic exercise and strength training versus control in mitochondrial
myopathy, Outcome 8 Myoglobin.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 3 Aerobic exercise and strength training versus control in mitochondrial myopathy
Outcome: 8 Myoglobin
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Lindeman 1995 15 20 (34) 15 41 (42) 100.0 % -21.00 [ -48.35, 6.35 ]
Total (95% CI) 15 15 100.0 % -21.00 [ -48.35, 6.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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44Strength training and aerobic exercise training for muscle disease (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.9. Comparison 3 Aerobic exercise and strength training versus control in mitochondrial
myopathy, Outcome 9 VO2 max in maximal incremental cycle exercise test.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 3 Aerobic exercise and strength training versus control in mitochondrial myopathy
Outcome: 9 VO2 max in maximal incremental cycle exercise test
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Cejudo 2005 9 400 (500) 9 0 (500) 100.0 % 400.00 [ -61.97, 861.97 ]
Total (95% CI) 9 9 100.0 % 400.00 [ -61.97, 861.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.70 (P = 0.090)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 Aerobic exercise and strength training versus control in myotonic dystrophy
type 1, Outcome 1 Distance walked in 6-minute walk test.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 4 Aerobic exercise and strength training versus control in myotonic dystrophy type 1
Outcome: 1 Distance walked in 6-minute walk test
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kierkegaard 2011 18 9 (116) 17 -2 (119) 100.0 % 11.00 [ -66.92, 88.92 ]
Total (95% CI) 18 17 100.0 % 11.00 [ -66.92, 88.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 4.2. Comparison 4 Aerobic exercise and strength training versus control in myotonic dystrophy
type 1, Outcome 2 Timed-stands test.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 4 Aerobic exercise and strength training versus control in myotonic dystrophy type 1
Outcome: 2 Timed-stands test
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kierkegaard 2011 18 -0.6 (7.2) 17 0.4 (9.9) 100.0 % -1.00 [ -6.76, 4.76 ]
Total (95% CI) 18 17 100.0 % -1.00 [ -6.76, 4.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 Aerobic exercise and strength training versus control in myotonic dystrophy
type 1, Outcome 3 Timed-up-and-go tests.
Review: Strength training and aerobic exercise training for muscle disease
Comparison: 4 Aerobic exercise and strength training versus control in myotonic dystrophy type 1
Outcome: 3 Timed-up-and-go tests
Study or subgroup Training Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Kierkegaard 2011 18 -0.5 (2.2) 17 0 (1.9) 100.0 % -0.50 [ -1.86, 0.86 ]
Total (95% CI) 18 17 100.0 % -0.50 [ -1.86, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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A P P E N D I C E S
Appendix 1. Cochrane Central Register of Controlled Trials (CENTRAL) (through Wiley
Interscience, The Cochrane Library 2012, Issue 7 of 12) search strategy
#1“muscle dis*” or “muscle weakness” or “muscular dis*” or “neuromuscular dis*” or myopath* or dystroph* or myotoni* or myositis
or polio* or “muscle fibre*” or “muscle strength” or fibromyalgia
#2“exercise therapy” or “exercise training” or “exercise program*” or “strength training” or “aerobic training” or “aerobic exercise” or
“training program” or “resistive exercise” or “endurance training” or “muscle exercise”
#3(#1 AND #2) (total database: 1299 hits)
Appendix 2. Cochrane Neuromuscular Disease Group Specialized Register search strategy
(“muscle dis*” or “muscle weakness” or “muscular dis*” or “neuromuscular dis*” or myopath* or dystroph* or myotoni* or myositis or
polio* or “muscle fibre*” or “muscle strength” or fibromyalgia) and (“exercise (therapy” or “exercise training” or “exercise program*”
or “strength training” or “aerobic training” or “aerobic exercise” or “training program” or “resistive exercise” or “endurance training”
or “muscle exercise”
Appendix 3. MEDLINE ( through OvidSP 1946 to 2012 July week 2) search strategy
1 (muscle disease* ormuscle disorder* or muscular disease* ormuscular disorder* or neuromuscular disease* or neuromuscular disorder*
or myopath* or dystroph* or myotoni* or myositis).mp. or exp muscle disease/
2 (exercise therap* or exercise program* or exercise training or strength training or aerobic training or aerobic exercis* or training
program* or resistive exercis* or resistiv training or endurance exercis* or endurance training or muscle exercis*).mp. or exp exercise/
or exp muscle exercise/ or exp excessive training/ or exp kinesiotherapy/
3 (trial* or random*).mp. or exp clinical trail/ or major clinical study/ or exp controlled study/
4 1 and 2 and 3 (total database: 820 hits)
Appendix 4. EMBASE ( through OvidSP 2012 week 30) and EMBASE Classic (through OvidSp)
search strategy
1 (muscle disease* ormuscle disorder* or muscular disease* ormuscular disorder* or neuromuscular disease* or neuromuscular disorder*
or myopath* or dystroph* or myotoni* or myositis).mp. or exp muscle disease/
2 (exercise therap* or exercise program* or exercise training or strength training or aerobic training or aerobic exercis* or training
program* or resistive exercis* or resistiv training or endurance exercis* or endurance training or muscle exercis*).mp. or exp exercise/
or exp muscle exercise/ or exp excessive training/ or exp kinesiotherapy/
3 (trial* or random*).mp. or exp clinical trail/ or major clinical study/ or exp controlled study/
4 1 and 2 and 3 (total database ’lim to Embase’: 5475 hits)
Appendix 5. Cumulative Index to Nursing and Allied Health Literature (CINAHL) (through
EBSCOhost 1982 to July 2012) search strategy
S1 TX (muscle disease* or muscle disorder* or muscular disease* or muscular disorder* or neuromuscular disease* or neuromuscular
disorder* or myopath* or dystroph* or myotoni* or myositis) or MH “Muscular Diseases+”
S2 TX (exercise therap* or exercise program* or exercise training or strength training or aerobic training or aerobic exercis* or training
program* or resistive exercis* or resistive training or endurance exercis* or endurance training or muscle exercis* ) or MH “Therapeutic
exercise+”
S3 TX Trial* OR Tx random* OR PT Systematic review OR PT Clinical trial OR MH “Clinical trials+”
S4 S1 and S2 and S3 (total database: 489 hits)
Search mode - Boolean/Phrase (July 31 2012)
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WH A T ’ S N E W
Last assessed as up-to-date: 2 July 2012.
Date Event Description
26 August 2012 New citation required and conclusions have changed Review updated to include a study of people with der-
matomyositis and polymyositis and a study with people
with myotonic dystrophy type I. The results and conclu-
sions of the review amended accordingly
2 July 2012 New search has been performed Searches updated to July 2012. One new trial identified
from searches. In this update we have included studies
with a exercise programme duration of at least six, instead
of 10, weeks. Therefore, one trial which was previously
excluded in the former update is now also included
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 1, 2005
Date Event Description
15 June 2011 Amended Additional acknowledgement added.
20 July 2009 New citation required and conclusions have changed Search updated to July 2009. Review updated to in-
clude a new study of people with mitochondrial my-
opathy (Cejudo 2005). The results and conclusions of
the review have been amended accordingly
2 July 2008 Amended Converted to new review format.
23 September 2004 New citation required and conclusions have changed Substantive amendment.
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C O N T R I B U T I O N S O F A U T H O R S
I Riphagen searched all databases. NBM Voet and EL van der Kooi identified and assessed potentially relevant studies, and extracted
the data from included studies. NBM Voet prepared the final draft. ACH Geurts, EL van der Kooi and E Lindeman edited each draft
and approved the final text of the review.
Eline Lindeman died in September 2012, but contributed to this update. There were moderately substantive changes to the review
subsequent to her involvement.
D E C L A R A T I O N S O F I N T E R E S T
E van der Kooi carried out a RCT on the effect of strength training and albuterol in FSHD (van der Kooi 2004).
E Lindeman: author deceased; declarations of interest in previously published version of the review: “Another [author] (Lindeman) has
co-ordinated a RCT on the effects of strength training in myotonic dystrophy (Lindeman 1995)”.
ACH Geurts: “Other than being the principle investigator in the Facts-2-FSHD trial (not yet published) on the effects of cognitive
behavioural therapy and physical exercises on chronic fatigue in patients with FSHD, I have no competing interests.”
II Riphagen: none known.
NBM Voet: none known.
Dr. van Engelen is research director of the European Neuromuscular Centre and receives institutional support from the Radboud
University Nijmegen Medical Centre and the ENMC, grant support from the Global FSH, Netherlands Organization for Scientific
Research, Prinses Beatrix Fonds, and the Dutch FSHD Foundation.
S O U R C E S O F S U P P O R T
Internal sources
• New Source of support, Not specified.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
As stated in a previous update, we excluded all studies using a within-subjects design with the non-exercised limb as a control (Aitkens
1993; De Lateur 1979; Kilmer 1994; McCartney 1988; Tollbäck 1999).
At this update (2012) additional changes were:
• inclusion of exercise programmes with a minimum duration of six, rather than 10 weeks as previously specified. Because of this
change of protocol, we included one trial which was excluded in the previous update (Wiesinger 1998a) and one new trial
(Kierkegaard 2011);
• we added a statement that we would exclude studies in which outcomes were not presented separately for each muscle disease.
One randomised controlled strength training combined with aerobic exercise trial has been excluded for this reason. No specific
details about the exercise programme were provided and the methodological quality of the trial was considered poor (Dawes 2006);
• we updated the definitions in Types of interventions;
• we have updated and changed the diagnostic criteria to ’confirmed by muscle biopsy or genetic testing’;
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• we have updated the exercise guidelines (Garber 2011);
• we searched the Cochrane Rehabilitation and Related Therapies Field Register in October 2002, August 2008 and July 2009.
As, in the past, it yielded no results and is no longer available, it has been removed from the Methods section.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Exercise; Dermatomyositis [rehabilitation]; Mitochondrial Myopathies [rehabilitation]; Muscular Diseases [∗rehabilitation]; Muscular
Dystrophy, Facioscapulohumeral [rehabilitation]; Myotonic Dystrophy [rehabilitation]; Physical Fitness; Polymyositis [rehabilitation];
Randomized Controlled Trials as Topic; Resistance Training [∗methods]
MeSH check words
Humans
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